PMID- 2272151
OWN - NLM
STAT- MEDLINE
DCOM- 19910228
LR  - 20131121
IS  - 0278-2677 (Print)
IS  - 0278-2677 (Linking)
VI  - 9
IP  - 11
DP  - 1990 Nov
TI  - Moricizine: a new class I antiarrhythmic.
PG  - 842-52
AB  - The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse 
      effects, and dosage of the Class I antiarrhythmic agent moricizine hydrochloride 
      are reviewed. Moricizine is chemically similar to the phenothiazines but does not 
      appear to block dopaminergic receptors. Its major electrophysiologic actions are 
      a concentration-dependent decrease in maximum rate of phase 0 depolarization; 
      increased rates of phase 2 and 3 repolarization, decreased action potential 
      duration, and decreased effective refractory period. Moricizine causes a 
      dose-related prolongation of the PR interval and of AV nodal, infranodal, and 
      intraventricular conduction times but has little effect on ventricular 
      repolarization. The antiarrhythmic and electrophysiologic effects are not 
      correlated with plasma concentrations of the drug or its metabolites. Moricizine 
      reduces the occurrence of ventricular premature contractions (VPCs), couplets, 
      and nonsustained ventricular tachycardia. It appears to suppress symptomatic 
      nonsustained ventricular tachycardia, sustained ventricular tachycardia, and 
      ventricular fibrillation or flutter. Moricizine appears to be as effective as 
      quinidine and more effective than disopyramide, propranolol, and imipramine but 
      less effective than flecainide and encainide at reducing VPCs. Moricizine 
      continues to be evaluated in the Cardiac Arrhythmia Suppression Trial, which was 
      designed to assess the long-term benefit of arrhythmia suppression in patients 
      with left ventricular dysfunction after myocardial infarction. Moricizine seems 
      to be better tolerated than quinidine, disopyramide, and imipramine and to have 
      less proarrhythmic potential than flecainide or encainide. Noncardiac adverse 
      effects include dizziness, nausea, and headache. Cimetidine appears to decrease 
      moricizine clearance, and decreased theophylline clearance has been reported in 
      subjects given moricizine. The usual adult dosage of moricizine hydrochloride is 
      600-900 mg/day given in three divided doses; an every-12-hour regimen may be used 
      in some patients. Because of the risk of proarrhythmic effects, indications are 
      limited to treatment of documented life-threatening arrhythmias. Moricizine will 
      compete with other agents as first-line therapy for life-threatening arrhythmias.
FAU - Mann, H J
AU  - Mann HJ
AD  - Department of Pharmacy Practice, College of Pharmacy, University of Minnesota, 
      Minneapolis 55455.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Pharm
JT  - Clinical pharmacy
JID - 8207437
RN  - 2GT1D0TMX1 (Moricizine)
SB  - IM
MH  - Arrhythmias, Cardiac/drug therapy
MH  - Drug Interactions
MH  - Humans
MH  - Moricizine/chemistry/pharmacokinetics/*pharmacology/therapeutic use
RF  - 59
EDAT- 1990/11/01 00:00
MHDA- 1990/11/01 00:01
CRDT- 1990/11/01 00:00
PHST- 1990/11/01 00:00 [pubmed]
PHST- 1990/11/01 00:01 [medline]
PHST- 1990/11/01 00:00 [entrez]
PST - ppublish
SO  - Clin Pharm. 1990 Nov;9(11):842-52.